Overview

A Study to Compare the Use of Ferric Carboxymaltose With Placebo in Patients With Chronic Heart Failure and Iron Deficiency

Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine, relative to placebo, the effect of iron repletion therapy using intravenous (IV) ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency.
Phase:
Phase 4
Details
Lead Sponsor:
Vifor Inc.
Vifor Pharma
Collaborator:
ICON Clinical Research
Treatments:
Ferric Compounds